Allergan PLC. (NYSE:AGN)‘s stock had its “outperform” rating reissued by research analysts at Wells Fargo & Company in a research report issued on Thursday, November 2nd, The Fly reports. They presently have a $245.00 target price on the stock, down from their previous target price of $258.00. Wells Fargo & Company’s price target points to a potential upside of 43.55% from the company’s previous close.
Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a report on Tuesday, July 11th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $231.00 target price on shares of Allergan PLC. in a report on Friday, July 14th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Sunday, July 16th. Deutsche Bank AG reissued a “buy” rating and issued a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $286.00 price target (up previously from $274.00) on shares of Allergan PLC. in a report on Thursday, July 20th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $246.73.
Allergan PLC. (AGN) traded down $0.45 on Thursday, hitting $170.67. 2,957,291 shares of the stock traded hands, compared to its average volume of 2,910,291. Allergan PLC. has a 1 year low of $169.61 and a 1 year high of $256.80. The stock has a market capitalization of $56,910.00, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.11 and a beta of 1.12. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.
Allergan PLC. (NYSE:AGN) last released its earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.06 by $0.09. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same period last year, the business earned $3.32 EPS. Allergan PLC.’s revenue for the quarter was up 11.4% on a year-over-year basis. equities analysts predict that Allergan PLC. will post 16.28 earnings per share for the current year.
Allergan PLC. declared that its Board of Directors has initiated a stock repurchase plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/allergan-plc-s-agn-outperform-rating-reiterated-at-wells-fargo-company/1750941.html.
Large investors have recently bought and sold shares of the stock. Honeywell International Inc. lifted its stake in shares of Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after buying an additional 20,100 shares in the last quarter. Israel Discount Bank of New York purchased a new stake in Allergan PLC. during the first quarter valued at approximately $988,000. Sumitomo Life Insurance Co. increased its holdings in Allergan PLC. by 39.0% during the third quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock valued at $3,099,000 after buying an additional 4,244 shares during the last quarter. Colony Group LLC increased its holdings in Allergan PLC. by 9.9% during the second quarter. Colony Group LLC now owns 39,802 shares of the company’s stock valued at $9,675,000 after buying an additional 3,577 shares during the last quarter. Finally, Palladium Partners LLC increased its holdings in Allergan PLC. by 1.7% during the second quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after buying an additional 523 shares during the last quarter. 81.65% of the stock is currently owned by institutional investors and hedge funds.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.